Heron Neutron Medical Corp. Launches International 18F-FBPA Research Collaboration with NUS Medicine

Heron Neutron Medical Corp. Launches International 18F-FBPA Research Collaboration with NUS Medicine

 

Heron Neutron Medical Corp. (Heron) today announced a new research collaboration with the Clinical Imaging Research Centre (CIRC), based at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), focused on 18F-FBPA-related molecular imaging technologies and translational research. The collaboration is intended to strengthen the scientific foundation for the international development of Boron Neutron Capture Therapy (BNCT) and support future advances in integrated theranostic approaches in overseas markets.

 Built around academic exchange and research collaboration, the initiative will bring together Heron’s long-standing expertise in BNCT and CIRC’s strengths in molecular imaging, and clinical translational research. In addition, CIRC offers advanced radiochemistry capabilities, including expertise in the development, production, and clinical translation of radiopharmaceuticals, supported by state-of-the-art academic cyclotron and GMP infrastructure. Through this partnership, the parties will explore the broader application potential of BNCT-related molecular imaging technologies and seek to advance innovation in this emerging field through access to high-quality international research resources.

 NUS Medicine has long been recognized for its emphasis on interdisciplinary research and medical innovation, and remains one of Asia’s leading institutions in biomedical research. For Heron, this collaboration with an NUS-affiliated research center marks an important step in expanding its global research network and creating new opportunities for higher-level academic exchange, technology validation, and future clinical application research across the region.

 

In parallel, Heron will also engage in clinical research in Singapore with a focus on overseas clinical development opportunities and integrated theranostic models in Southeast Asia. Given the short half-life of radioactive 18F tracers and the importance of timely preparation and supply, the collaboration is expected to help inform future development strategies by leveraging Singapore’s strong clinical research, radiochemistry and molecular imaging capabilities. Heron believes this will further open the door to innovation and broader international collaboration in BNCT-related technologies.

 “Heron has always placed great importance on both independent innovation and international collaboration in key BNCT technologies,” said Leo Shen, General Manager of Heron “Looking ahead, under appropriate regulatory and research frameworks, we will continue to deepen our partnerships with leading academic and clinical institutions worldwide, advance the research and application development of BNCT-related technologies, and contribute to stronger medical technology collaboration and innovation across Asia.